vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and FIRST COMMONWEALTH FINANCIAL CORP (FCF). Click either name above to swap in a different company.
FIRST COMMONWEALTH FINANCIAL CORP is the larger business by last-quarter revenue ($133.7M vs $83.5M, roughly 1.6× BillionToOne, Inc.). FIRST COMMONWEALTH FINANCIAL CORP runs the higher net margin — 28.1% vs 6.8%, a 21.2% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 13.0%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
BLLN vs FCF — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $133.7M |
| Net Profit | $5.7M | $37.5M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 28.1% |
| Revenue YoY | 117.4% | 13.0% |
| Net Profit YoY | 138.3% | 14.8% |
| EPS (diluted) | $0.10 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $133.7M | ||
| Q4 25 | — | $137.9M | ||
| Q3 25 | $83.5M | $136.0M | ||
| Q2 25 | — | $131.0M | ||
| Q1 25 | — | $118.0M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | $38.4M | $121.2M | ||
| Q2 24 | — | $120.2M |
| Q1 26 | — | $37.5M | ||
| Q4 25 | — | $44.9M | ||
| Q3 25 | $5.7M | $41.3M | ||
| Q2 25 | — | $33.4M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | — | $35.8M | ||
| Q3 24 | $-14.9M | $32.1M | ||
| Q2 24 | — | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 40.9% | ||
| Q3 25 | 11.5% | 38.1% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 34.8% | ||
| Q4 24 | — | 37.1% | ||
| Q3 24 | -32.9% | 33.4% | ||
| Q2 24 | — | 38.7% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | 32.5% | ||
| Q3 25 | 6.8% | 30.4% | ||
| Q2 25 | — | 25.5% | ||
| Q1 25 | — | 27.7% | ||
| Q4 24 | — | 29.8% | ||
| Q3 24 | -38.8% | 26.5% | ||
| Q2 24 | — | 30.9% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | — | $0.44 | ||
| Q3 25 | $0.10 | $0.39 | ||
| Q2 25 | — | $0.32 | ||
| Q1 25 | — | $0.32 | ||
| Q4 24 | — | $0.35 | ||
| Q3 24 | $-1.47 | $0.31 | ||
| Q2 24 | — | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | — |
| Total DebtLower is stronger | $55.0M | $154.9M |
| Stockholders' EquityBook value | $-239.5M | $1.6B |
| Total Assets | $327.5M | $12.3B |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $195.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $154.9M | ||
| Q4 25 | — | $261.7M | ||
| Q3 25 | $55.0M | $262.1M | ||
| Q2 25 | — | $262.4M | ||
| Q1 25 | — | $262.7M | ||
| Q4 24 | — | $263.0M | ||
| Q3 24 | — | $136.3M | ||
| Q2 24 | — | $136.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | $-239.5M | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $-242.9M | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $12.3B | ||
| Q4 25 | — | $12.3B | ||
| Q3 25 | $327.5M | $12.3B | ||
| Q2 25 | — | $12.2B | ||
| Q1 25 | — | $11.8B | ||
| Q4 24 | — | $11.6B | ||
| Q3 24 | — | $12.0B | ||
| Q2 24 | — | $11.6B |
| Q1 26 | — | 0.10× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $187.5M | ||
| Q3 25 | $13.8M | $49.5M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $55.9M | ||
| Q4 24 | — | $129.5M | ||
| Q3 24 | — | $53.6M | ||
| Q2 24 | — | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $171.5M | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $113.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 124.3% | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 94.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 11.7% | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 12.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.18× | ||
| Q3 25 | 2.42× | 1.20× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.71× | ||
| Q4 24 | — | 3.61× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
FCF
Segment breakdown not available.
